<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02262130</url>
  </required_header>
  <id_info>
    <org_study_id>P/2013/209</org_study_id>
    <nct_id>NCT02262130</nct_id>
  </id_info>
  <brief_title>Omalizumab in Severe and Refractory Solar Urticaria</brief_title>
  <acronym>XOLUS</acronym>
  <official_title>Phase 2 Multicentric Study Evaluating the Efficacy of Omalizumab in Idiopathic Severe and Refractory Solar Urticaria</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Besancon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Besancon</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Solar urticaria is a rare disease, with a usual favourable outcome with photoprotection and
      with anti H1 histamines. Nevertheless, some cases can be severe and refractory to this usual
      treatment, leading to a large impact on quality of life. New treatment options are warranted.
      The investigators aim to test the efficacy and the safety of omalizumab, an anti-IgE antibody
      recently approved in chronic spontaneous urticaria, in this setting.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an open-labelled multicentric phase II study testing the efficacy and the safety of
      omalizumab 300 mg (W0, W4 and W8) in patients affected with severe and refractory solar
      urticaria.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2014</start_date>
  <completion_date type="Actual">September 2015</completion_date>
  <primary_completion_date type="Actual">September 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients with remission of solar urticaria under experimental conditions (photesting)</measure>
    <time_frame>4 weeks after the end of treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients having a small effect on quality of life (DLQI &lt; 6)</measure>
    <time_frame>4 and 12 weeks after the end of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with SU remission under experimental conditions (phototesting)</measure>
    <time_frame>12 weeks after the end of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients achieving 50% improvement in solar urticaria intensity (VAS)</measure>
    <time_frame>4 and 12 weeks after the end of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients achieving clinical remission of SU</measure>
    <time_frame>4 and 12 weeks after the end of treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Solar Urticaria</condition>
  <arm_group>
    <arm_group_label>Omalizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Omalizumab 300 mg W0, W4 and W8</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Omalizumab</intervention_name>
    <arm_group_label>Omalizumab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt; or equal to 18 years,

          -  Appearance of wheals within 15 min after sun exposure and lasting &lt; 2 hr in the shade,

          -  Wheals reproducible with phototesting: appearance after exposure to UVB, UVA or
             visible light less than 30 min after exposure and lasting &lt; 2 hr,

          -  Severity criteria:

               -  Very large effect on quality of life, with Dermatology Life Quality Index (DLQI)
                  &gt; 10, and

               -  At least 1 of the following: involvement of the face, per annual eruption,
                  extension of wheals on the non-photoexposed skin, SU triggered by artificial
                  light, SU flares accompanied by bronchospasm or syncope.

          -  Refractory criteria:

               -  Resistance to photoprotection with sunscreen with sun protection factor ≥ 50, and

               -  Resistance to administration of an association of 2 different antihistamines
                  during 3 months or to photodesensitization.

        Exclusion Criteria:

          -  Contra indication to omalizumab

          -  Previous treatment with omalizumab
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Manuelle Viguier, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assistance Publique-Hôpitaux de Paris, Université Paris 7</affiliation>
  </overall_official>
  <overall_official>
    <last_name>François AUBIN, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Hospitalier régional Universitaire de Besançon</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CHU de Angers</name>
      <address>
        <city>Angers</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermatology department, Centre Hospitalier Régional Universitaire</name>
      <address>
        <city>Besançon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Caen</name>
      <address>
        <city>Caen</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Dijon</name>
      <address>
        <city>Dijon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Grenoble</name>
      <address>
        <city>Grenoble</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHRU de Lille</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Limoges</name>
      <address>
        <city>Limoges</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Montpellier</name>
      <address>
        <city>Montpellier</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Nancy</name>
      <address>
        <city>Nancy</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermatology department, Hôpital Saint-Louis</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Reims</name>
      <address>
        <city>Reims</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Rennes</name>
      <address>
        <city>Rennes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Toulouse</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>November 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 7, 2014</study_first_submitted>
  <study_first_submitted_qc>October 9, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 10, 2014</study_first_posted>
  <last_update_submitted>November 26, 2015</last_update_submitted>
  <last_update_submitted_qc>November 26, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 30, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Omalizumab</keyword>
  <keyword>Efficacy</keyword>
  <keyword>Safety</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urticaria</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Omalizumab</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>March 24, 2017</submitted>
    <returned>May 3, 2017</returned>
    <submitted>July 27, 2017</submitted>
    <submission_canceled>Unknown</submission_canceled>
    <submitted>December 6, 2017</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

